-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Tampa, Florida
Researchers at the Lung Cancer Center of Excellence at Moffitt Cancer Center believe that a combination of checkpoint inhibitors and adoptive cell therapy may be the answer for these patients
Non-small cell lung cancer tumors are usually classified as "cold" tumors, which means that the tumor is not infiltrated by immune cells and therefore it is difficult to respond to immunotherapy
"These results give hope that cell therapy can be added to lung cancer treatment equipment
Twenty patients with non-small cell lung cancer were included in the preliminary study
Before TIL treatment, each patient received niluzumab treatment
The researchers successfully expanded the TIL infusion in 95% of patients, and 16 of the 20 patients received TIL infusion because their disease progressed after the initial niluzumab treatment
After the treatment, the researchers conducted additional studies and confirmed that the patient's T cells respond to a variety of different tumor-specific proteins, including genetically mutated proteins
"Our data show that TIL can mediate effective tumor responses to subtypes that are not sensitive to traditional immune checkpoint targeted therapies
A new study is under development to improve the production of TIL and expand the detection of oncogene-driven lung cancer patients whose tumors are progressing under the action of targeted drugs
